Author + information
- Received August 7, 2008
- Revision received January 27, 2009
- Accepted February 6, 2009
- Published online June 16, 2009.
- ↵⁎Reprint requests and correspondence:
Dr. Edward T. H. Yeh, The University of Texas M. D. Anderson Cancer Center, Department of Cardiology, 1400 Pressler Street, Room 11.5028, Houston, Texas 77030
Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prolong life and provide cure. However, many of these treatments can cause cardiovascular complications such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. In this article we review the incidence of cardiotoxicity caused by commonly used chemotherapeutic agents as well as discuss the pathogenesis, diagnosis, management, and prevention of these cardiovascular side effects. Cardiotoxicity related to anticancer treatment is important to recognize as it may have a significant impact on the overall prognosis and survival of cancer patients, and it is likely to remain a significant challenge for both cardiologists and oncologists in the future due to an increasing aging population of patients with cancer and the introduction of many new cancer therapies.
Dr. Yeh is a consultant for Celgene and is the McNair Scholar of the Texas Heart Institute.
- Received August 7, 2008.
- Revision received January 27, 2009.
- Accepted February 6, 2009.
- American College of Cardiology Foundation